Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC)

scientific article published on 24 September 2018

Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC) is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.CLLC.2018.09.015
P698PubMed publication ID30343004

P50authorMara B AntonoffQ61194092
Marcelo Vailati NegrãoQ85615104
John V HeymachQ88721314
Stephen SwisherQ89454225
Vassiliki PapadimitrakopoulouQ94475620
P2093author name stringJeff Lewis
Jack A Roth
Jianjun Zhang
Daniel R Gomez
Lara Lacerda
Hai Tran
Yasir Y Elamin
Jacqulyne P Robichaux
Xiuning Le
Emily B Roarty
Jadi M Bohac
Melissa K Shorter
Waree Rinsurogkawong
P433issue1
P407language of work or nameEnglishQ1860
P304page(s)43-47
P577publication date2018-09-24
P1433published inClinical Lung CancerQ332299
P1476titleLocal Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC)
P478volume20